OXFORD BIOMEDICA PLC APPOINTS NICK L WOOLF SENIOR VICE PRESIDENT OF CORPORATE STRATEGY

Oxford, UK 17 September 2002 - Oxford BioMedica Plc (LSE: OXB) announced today that it has strengthened its senior management with the appointment of Nick L.Woolf as Senior Vice President of Corporate Strategy. 

With more than eight years experience as a biotechnology and pharmaceutical analyst, Nick has been involved in all aspects of company financing, ranging from IPOs to major corporate deals. Most recently he served as Director and Head of European Biotechnology Research at ABN AMRO, where he was responsible for developing its industry coverage. Prior to that, Nick was Vice President, and Senior Analyst at Robertson Stephens International where he established its European biotechnology research product, and was previously at both Nomura and SBC Warburg. Nick holds a MA from Oxford University in Chemistry.

Alan Kingsman, Chief Executive of Oxford BioMedica, said:
“I am delighted to welcome Nick Woolf to the management team. Nick will be of great benefit to the Company as we continue to develop our business. He brings with him a wealth of industry knowledge and capital markets experience, which I believe will both strengthen and complement the management team already in place.”

-Ends- 

Notes to Editors

1. Oxford BioMedica plc
Established in 1995 as a spin out from Oxford University, Oxford BioMedica is an international biotechnology company with a diverse portfolio of products and technology, specialising in gene-based products and technology in the areas of cancer, neurological disease, cardiovascular disease and blood disorders. This is underpinned by over 70 patent families, about quarter of which are issued. Oxford BioMedica plc was floated on the Alternative Investment Market of the London Stock Exchange in December 1996, and was promoted to the United Kingdom Listing Authority Official List in April 2001 following a successful £35.5 million fund-raising. 

Oxford BioMedica is headquartered in Oxford, UK and has a wholly-owned subsidiary in San Diego, USA.

Currently Oxford BioMedica has corporate collaborations with Amersham, Arius, Aventis, IDM, Valentis, Virbac and Wyeth. BioMedica has two products in Phase I/II clinical trials: MetXia® for late-stage breast cancer, and TroVax® for late-stage colorectal cancer. 

2. World Wide Web
Further information is available on the World Wide Web at www.oxfordbiomedica.co.uk